In this interview, touchHAEMATOLOGY are joined by Professor Per Ljungman (Karolinska University Hospital, Stockholm, Sweden) to discuss the updated results of the EBMT COVID-19 Task Force study exploring study exploring the outcomes and mortality in cytomegalovirus seropositive allogeneic stem cell transplantation patients with COVID-19.
Questions
1. Please describe the rationale and main aims of your study exploring outcomes and mortality in cytomegalovirus seropositive allogeneic stem cell transplantation patients with COVID-19? (00:16)
2. What was the study design? (00:55)
3. Please summarize the most important findings of the study (01:31)
4. What conclusions were made, and how might this impact future investigations or treatment plans? (02:20)
Disclosures: Per Ljungman has no financial or non-financial conflicts of interest to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Additional resources:
